Neurochemical approaches in the laboratory diagnosis of parkinson and parkinson dementia syndromes: A review

CNS Neuroscience and Therapeutics

Volumn 15, Issue 2, 2009, Pages 157-182

  Jesse, Sarah ^a   Steinacker, Petra ^a   Lehnert, Stefan ^a   Gillardon, Frank ^b   Hengerer, Bastian ^b   Otto, Markus ^a  

^a UNIVERSITY OF ULM   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Differential diagnosis; Multisystem atrophy; Neurochemical diagnosis; Parkinson dementia; Parkinson disease; Progressive supranuclear palsy

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN; BIOLOGICAL MARKER; CATECHOLAMINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; COBALT; DOPAMINE RECEPTOR STIMULATING AGENT; FATTY ACID BINDING PROTEIN; GROWTH HORMONE; HEAT SHOCK PROTEIN 70; INDOLEAMINE; LEVODOPA; NEUROTRANSMITTER; OREXIN; OSTEOPONTIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; REELIN; TAU PROTEIN; TETRAHYDROBIOPTERIN;

ADRENERGIC ACTIVITY; ALZHEIMER DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOPAMINERGIC ACTIVITY; EARLY DIAGNOSIS; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; LIPID PEROXIDATION; NARCOLEPSY; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROFILAMENT; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PREDICTION; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEOMICS; RESPIRATORY CHAIN; REVIEW; SEROTONINERGIC SYSTEM;

CLINICAL LABORATORY TECHNIQUES; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE SYSTEM ATROPHY; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 65549111767     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00064.x     Document Type: Review

References (135)

1. Weintraub D, Comella CL, Horn S. Parkinson's disease - Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 2008 14 (2 Suppl. S40 S48.
2. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005 123 : 383 396. (Pubitemid 41546670)
3. Di Napoli M, Shah IM, Stewart DA. Molecular pathways and genetic aspects of Parkinson's disease: From bench to bedside. Expert Rev Neurother 2007 7 : 1693 1729. (Pubitemid 350262714)
4. Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT. Rotenone model of Parkinson disease: Multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J Biol Chem 2005 280 : 42026 42035. (Pubitemid 43023171)
5. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004 4 : 3943 3952. (Pubitemid 39657469)
6. Chandra S, Fornai F, Kwon HB, et al. Double-knockout mice for alpha- and beta-synucleins: Effect on synaptic functions. Proc Natl Acad Sci USA 2004 101 : 14966 14971. (Pubitemid 39410782)
7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 24 : 197 211. (Pubitemid 36007810)
8. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006 396 : 67 72. (Pubitemid 43233790)
9. Caballol N, Marti MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007 22 (Suppl. 17 S358 S366. (Pubitemid 350134189)
10. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997 244 : 2 8. (Pubitemid 26413891)
11. Pillon B, Dubois B, Ploska A, Agid Y. Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 1991 41 : 634 643.
12. Rongve A, Aarsland D. Management of Parkinson's disease dementia: Practical considerations. Drugs Aging 2006 23 : 807 822. (Pubitemid 44664671)
13. Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord 2003 18 (Suppl. 6 S63 S71. (Pubitemid 37185198)
14. Weiner WJ. A differential diagnosis of Parkinsonism. Rev Neurol Dis 2005 2 : 124 131. (Pubitemid 41407666)
15. Wakabayashi K, Takahashi H. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration. Neuropathology. 2004 24 : 79 86. (Pubitemid 38391499)
16. Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy: Pathology and genetics. Brain Pathol 2007 17 : 74 82. (Pubitemid 46310688)
17. El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003 17 : 1945 1947.
18. Selkoe DJ. Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004 6 : 1054 1061. (Pubitemid 39468006)
19. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 2001 276 : 10737 10744. (Pubitemid 38089246)
20. Fink AL. The aggregation and fibrillation of alpha-synuclein. Acc Chem Res 2006 39 : 628 634.
21. Kahle PJ, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 2000 20 : 6365 6373. (Pubitemid 32266067)
22. Chamberlain LH, Burgoyne RD. Cysteine-string protein: The chaperone at the synapse. J Neurochem 2000 74 : 1781 1789. (Pubitemid 30217632)
23. Braun JE, Wilbanks SM, Scheller RH. The cysteine string secretory vesicle protein activates Hsc70 ATPase. J Biol Chem 1996 271 : 25989 25993. (Pubitemid 26347435)
24. Jakowec MW, Petzinger GM, Sastry S, Donaldson DM, McCormack A, Langston JW. The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Neurosci Lett 1998 253 : 13 16. (Pubitemid 28417007)
25. Borghi R, Marchese R, Negro A, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 2000 287 : 65 67. (Pubitemid 30332379)
26. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006 20 : 419 425.
27. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 2006 113 : 1435 1439. (Pubitemid 44435881)
28. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006 349 : 162 166. (Pubitemid 44331776)
29. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008 213 : 315 325.
30. Zhu M, Fink AL. Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem 2003 278 : 16873 16877. (Pubitemid 36799558)
31. Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007 130 (Pt 6 1577 1585. (Pubitemid 47355929)
32. Jellinger KA. The pathology of Parkinson's disease. Adv Neurol 2001 86 : 55 72.
33. Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978 3 : 129 133.
34. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002 59 : 1553 1562.
35. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007 130 (Pt 6 1586 1595. (Pubitemid 47355933)
36. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967 17 : 427 442. (Pubitemid 33596369)
37. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2006 250 : 120 123. (Pubitemid 44665944)
38. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti CL. Parkinsonism with excessive daytime sleepiness - a narcolepsy-like disorder? J Neurol 2005 252 : 139 145. (Pubitemid 40385585)
39. Korczynski W, Ceregrzyn M, Matyjek R, et al. Central and local (enteric) action of orexins. J Physiol Pharmacol 2006 57 (Suppl. 6 17 42. (Pubitemid 46548799)
40. Fesus L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival. FEBS Lett 2005 579 : 3297 3302. (Pubitemid 40804677)
41. Ruan Q, Johnson GV. Transglutaminase 2 in neurodegenerative disorders. Front Biosci 2007 12 : 891 904. (Pubitemid 46846864)
42. Vermes I, Steur EN, Jirikowski GF, Haanen C. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov Disord 2004 19 : 1252 1254. (Pubitemid 39429976)
43. Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J 2004 18 : 932 934.
44. Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 2003 100 : 2047 2052. (Pubitemid 36254571)
45. Sarvari M, Fesus L, Nemes Z. Transglutaminase-mediated crosslinking of neural proteins in Alzheimer's diseases and other primary dementias. Drug Dev Res 2002 56 : 458 472. (Pubitemid 35168323)
46. Segers-Nolten I, Wilhelmus M, Veldhuis G, van Rooijen BD, Drukarch B, Subramaniam V. Tissue transglutaminase modulates alpha-synuclein oligomerization. Protein Sci 2008 17 : 1395 1402.
47. Wilhelmus MM, van Dam AM, Drukarch B. Tissue transglutaminase: A novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur J Pharmacol 2008 585 : 464 472.
48. Suzuki T, Nakaya T. Regulation of APP by phosphorylation and protein interactions. J Biol Chem 2008, in press. (Pubitemid 47484031)
49. Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer's disease: Total tau, phospho-tau and Abeta42. World J Biol Psychiatry 2003 4 : 147 155.
50. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008 64 : 850 855.
51. Sjogren M, Minthon L, Davidsson P, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000 107 : 563 579. (Pubitemid 30251740)
52. Sjogren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001 70 : 624 630. (Pubitemid 32397998)
53. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003 18 : 186 190. (Pubitemid 36305463)
54. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006 22 : 200 208. (Pubitemid 44310515)
55. Mollenhauer B, Bibl M, Esselmann H, et al. Tauopathies and synucleinopathies: Do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm 2007 114 : 919 927. (Pubitemid 47013596)
56. Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006 129 (Pt 5 1177 1187. (Pubitemid 44310515)
57. Bibl M, Esselmann H, Mollenhauer B, et al. Blood-based neurochemical diagnosis of vascular dementia: A pilot study. J Neurochem 2007 103 : 467 474. (Pubitemid 47498016)
58. Rice DS, Curran T. Role of the reelin signaling pathway in central nervous system development. Annu Rev Neurosci 2001 24 : 1005 1039. (Pubitemid 32695252)
59. Ohkubo N, Lee YD, Morishima A, et al. Apolipoprotein E and reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/ glycogen synthase kinase-3beta cascade. FASEB J 2003 17 : 295 297.
60. Botella-Lopez A, Burgaya F, Gavin R, et al. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc Natl Acad Sci USA 2006 103 : 5573 5578.
61. Chin J, Massaro CM, Palop JJ, et al. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J Neurosci 2007 27 : 2727 2733. (Pubitemid 46438989)
62. Saez-Valero J, Costell M, Sjogren M, Andreasen N, Blennow K, Luque JM. Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. J Neurosci Res 2003 72 : 132 136. (Pubitemid 36373819)
63. Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 2007 104 : 955 960. (Pubitemid 46154718)
64. Kawamoto Y, Akiguchi I, Shirakashi Y, et al. Accumulation of Hsc70 and Hsp70 in glial cytoplasmic inclusions in patients with multiple system atrophy. Brain Res 2007 1136 : 219 227. (Pubitemid 46209080)
65. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007 28 : 742 747. (Pubitemid 46349352)
66. Brettschneider J, Petzold A, Sussmuth SD, et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006 21 : 2224 2227. (Pubitemid 46140444)
67. Abdo WF, van de Warrenburg BP, Munneke M, et al. CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 2006 67 : 474 479. (Pubitemid 44214973)
68. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation. J Biol Chem 1994 269 : 15957 15960. (Pubitemid 24209273)
69. Loebermann H, Tokuoka R, Deisenhofer J, Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 1984 177 : 531 557. (Pubitemid 15244823)
70. Davis RL, Holohan PD, Shrimpton AE, et al. Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol 1999 155 : 1901 1913. (Pubitemid 29454960)
71. Bradshaw CB, Davis RL, Shrimpton AE, et al. Cognitive deficits associated with a recently reported familial neurodegenerative disease: Familial encephalopathy with neuroserpin inclusion bodies. Arch Neurol 2001 58 : 1429 1434. (Pubitemid 32845995)
72. Matsubara E, Hirai S, Amari M, et al. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990 28 : 561 567. (Pubitemid 20359164)
73. Pirttila T, Mehta PD, Frey H, Wisniewski HM. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol Aging 1994 15 : 313 317. (Pubitemid 2093755)
74. Nielsen HM, Minthon L, Londos E, et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 2007 69 : 1569 1579. (Pubitemid 350287140)
75. Tanaka S, Yamada M, Kitahara S, Higuchi T, Honda K, Kamijima K. Induction of neuroserpin expression in rat frontal cortex after chronic antidepressant treatment and electroconvulsive treatment. Nihon Shinkei Seishin Yakurigaku Zasshi 2006 26 : 51 56. (Pubitemid 44431027)
76. Abdo WF, De Jong D, Hendriks JC, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord 2004 19 : 571 579.
77. Chia LG, Cheng LJ, Chuo LJ, Cheng FC, Cu JS. Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. J Neurol Sci 1995 133 : 73 78.
78. Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995 52 : 237 245.
79. Mollenhauer B, Steinacker P, Bahn E, et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: Marker candidates for dementia with Lewy bodies. Neurodegener Dis 2007 4 : 366 375. (Pubitemid 47134683)
80. Mollenhauer B, Steinacker P, Bahn E, et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis 2007 4 : 366 375. (Pubitemid 47134683)
81. Wada-Isoe K, Imamura K, Kitamaya M, Kowa H, Nakashima K. Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci 2008 266 : 20 24.
82. Pellecchia MT, Pivonello R, Colao A, Barone P. Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. Clin Med Res 2006 4 : 322 325. (Pubitemid 46166381)
83. Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997 349 : 1877 1881. (Pubitemid 27270122)
84. Clarke CE, Ray PS, Speller JM. Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease. Lancet 1999 353 : 1329 1330. (Pubitemid 29178789)
85. Tranchant C, Guiraud-Chaumeil C, Echaniz-Laguna A, Warter JM. Is clonidine growth hormone stimulation a good test to differentiate multiple system atrophy from idiopathic Parkinson's disease? J Neurol 2000 247 : 853 856.
86. Strijks E, van't Hof M, Sweep F, Lenders JW, Oyen WJ, Horstink MW. Stimulation of growth-hormone release with clonidine does not distinguish individual cases of idiopathic Parkinson's disease from those with striatonigral degeneration. J Neurol 2002 249 : 1206 1210.
87. Lee EA, Kim BJ, Lee WY. Diagnosing multiple system atrophy with greater accuracy: Combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography. Mov Disord 2002 17 : 1242 1247. (Pubitemid 36041338)
88. Schaefer S, Vogt T, Nowak T, Kann PH. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy. J Neuroendocrinol 2008 20 : 104 109. (Pubitemid 350239154)
89. Pellecchia MT, Longo K, Manfredi M, et al. The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. Mov Disord 2008 23 : 190 194.
90. Hevel JM, Marletta MA. Macrophage nitric oxide synthase: Relationship between enzyme-bound tetrahydrobiopterin and synthase activity. Biochemistry 1992 31 : 7160 7165.
91. Heinzel B, John M, Klatt P, Bohme E, Mayer B. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992 281 (Pt 3 627 630.
92. Kuiper MA, Teerlink T, Visser JJ, Bergmans PL, Scheltens P, Wolters EC. L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm 2000 107 : 183 189. (Pubitemid 30095369)
93. Molina JA, Jimenez-Jimenez FJ, Gomez P, et al. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J Neurol Sci 1997 150 : 123 127. (Pubitemid 27317689)
94. Mally J, Szalai G, Stone TW. Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J Neurol Sci 1997 151 : 159 162. (Pubitemid 27421846)
95. Gao C, Guo H, Wei J, Kuo PC. Osteopontin inhibits expression of cytochrome c oxidase in RAW 264.7 murine macrophages. Biochem Biophys Res Commun 2003 309 : 120 125. (Pubitemid 36999767)
96. Maetzler W, Berg D, Schalamberidze N, et al. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 2007 25 : 473 482. (Pubitemid 46304237)
97. Iczkiewicz J, Rose S, Jenner P. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Exp Neurol 2007 207 : 95 106. (Pubitemid 47332486)
98. Scatena M, Liaw L, Giachelli CM. Osteopontin: A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007 27 : 2302 2309. (Pubitemid 350203943)
99. Youdim MB, Riederer P. The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J Neural Transm Suppl 1993 40 : 57 67. (Pubitemid 24005557)
100. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994 63 : 793 807. (Pubitemid 24266591)
101. Berg D, Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord 2006 21 : 1299 1310. (Pubitemid 44613277)
102. Takeda A. Manganese action in brain function. Brain Res Brain Res Rev 2003 41 : 79 87. (Pubitemid 36044595)
103. Rossi L, Lombardo MF, Ciriolo MR, Rotilio G. Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance. Neurochem Res 2004 29 : 493 504. (Pubitemid 38295000)
104. Yasui M, Kihira T, Ota K. Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology 1992 13 : 593 600.
105. Gutteridge JM, Quinlan GJ, Clark I, Halliwell B. Aluminium salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta 1985 835 : 441 447. (Pubitemid 15247855)
106. Birchall JD, Chappell JS. The chemistry of aluminum and silicon in relation to Alzheimer's disease. Clin Chem 1988 34 : 265 267. (Pubitemid 18064975)
107. Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994 36 : 876 881. (Pubitemid 24370927)
108. Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: A lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 2004 1012 : 306 325. (Pubitemid 38453534)
109. Miyajima H, Kono S, Takahashi Y, Sugimoto M. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis 2002 29 : 433 438.
110. Hochstrasser H, Bauer P, Walter U, et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004 63 : 1912 1917. (Pubitemid 39532390)
111. Hochstrasser H, Tomiuk J, Walter U, et al. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J 2005 19 : 1851 1853. (Pubitemid 41598772)
112. Forte G, Bocca B, Senofonte O, et al. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm 2004 111 : 1031 1040. (Pubitemid 39037124)
113. Forte G, Alimonti A, Pino A, et al. Metals and oxidative stress in patients with Parkinson's disease. Ann Ist Super Sanita 2005 41 : 189 195. (Pubitemid 43169863)
114. Qureshi GA, Qureshi AA, Memon SA, Parvez SH. Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy. J Neural Transm Suppl 2006 71 : 229 236.
115. Jimenez-Jimenez FJ, Molina JA, Aguilar MV, et al. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J Neural Transm 1998 105 : 497 505. (Pubitemid 28365032)
116. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001 276 : 44284 44296. (Pubitemid 37384003)
117. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: A histochemical and neurochemical study. Brain Res 1994 660 : 8 18. (Pubitemid 24301248)
118. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 2006 26 : 5256 5264. (Pubitemid 44315308)
119. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008 283 : 9089 1100.
120. Parker WD Jr., Parks JK, Swerdlow RH. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 2008 1189 : 215 218.
121. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 2004 58 : 39 46. (Pubitemid 38117047)
122. Gomez C, Bandez MJ, Navarro A. Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Front Biosci 2007 12 : 1079 1093. (Pubitemid 46846880)
123. Lenaz G, Baracca A, Fato R, Genova ML, Solaini G. Mitochondrial complex I: Structure, function, and implications in neurodegeneration. Ital J Biochem 2006 55 : 232 253. (Pubitemid 43741313)
124. Gillardon F, Mack M, Rist W, et al. MicroRNA and proteome expression profiling in early symptomatic alpha-synuclein(A30P) transgenic mice. Proteotomics Clin Appl 2008 2 : 697 705. (Pubitemid 352789089)
125. Miska EA, Alvarez-Saavedra E, Townsend M, et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 2004 5 : R68.
126. Bilen J, Liu N, Burnett BG, Pittman RN, Bonini NM. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell 2006 24 : 157 163. (Pubitemid 44466675)
127. Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004 36 : 375 379. (Pubitemid 39619844)
128. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003 302 : 819 822. (Pubitemid 37339614)
129. Jin J, Hulette C, Wang Y, et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: Relevance to Parkinson disease. Mol Cell Proteomics 2006 5 : 1193 1204. (Pubitemid 44103391)
130. Kaul SC, Duncan EL, Englezou A, et al. Malignant transformation of NIH3T3 cells by overexpression of mot-2 protein. Oncogene 1998 17 : 907 911. (Pubitemid 28430213)
131. Kaul SC, Yaguchi T, Taira K, Reddel RR, Wadhwa R. Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts. Exp Cell Res 2003 286 : 96 101. (Pubitemid 36506862)
132. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005 205 : 74 81. (Pubitemid 40029095)
133. Wadhwa R, Takano S, Taira K, Kaul SC. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J Gene Med 2004 6 : 439 444. (Pubitemid 40228060)
134. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006 9 : 293 348. (Pubitemid 44253348)
135. Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci 2008 6 : 8.